IACOR Comment on EU Clinical Trial Directive
IAOCR, a provider of independently recognized, competence-based accreditation, consultancy and accredited training for clinical research professionals, offered comment the new EU regulation for clinical trials planned for implementation May 28, 2016.
IAOCR, a provider of independently recognized, competence-based accreditation, consultancy and accredited training for clinical research professionals, offered comment the new EU regulation for clinical trials planned for implementation May 28, 2016.
Martin Robinson PhD, Executive VP & IAOCR Ambassador, commented, “These changes will work towards ensuring patient safety is at the forefront of clinical trials but the competence of those undertaking the trials is also required to ensure a robust, proficient and safe system is in place across Europe.”
The new regulation was approved by the European Parliament in April last year and has now been published in the official Journal of the European Union. It replaces directive 2001/20/EC – the Clinical Trial Directive which has been in place for almost a decade. The benefits associated with the new regulation include a single approval portal, standardized content of clinical trial applications, information about subject protection and informed consent, more stringent requirements for reporting trial progress and greater transparency about clinical trials. The regulation will be applied in full in all member states, with no need for separate national legislation and this will result in consistent and uniform application throughout EU allowing the EU Commission to conduct controls in Member States making sure that rules are properly supervised and enforced.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025